🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →
S&P 500: 670.79 +0.3% NASDAQ 100: 603.31 +0.5% Dow Jones: 470.90 +0.1%

Stanley Druckenmiller’s TEVA Holdings & Trades

First Buy
Q4 2013
Duration Held
12 Quarters
Largest Add
Q4 2024
+7.57 M Shares
Current Position
5.87 M Shares
$183.36 M Value

Stanley Druckenmiller's TEVA Position Overview

Stanley Druckenmiller (via Duquesne Family Office LLC) currently holds 5.87 M shares of Teva Pharmaceutical Industries Limited (TEVA) worth $183.36 M, representing 4.08% of the portfolio. First purchased in 2013-Q4, this medium-term investment has been held for 12 quarters.

Based on 13F filings, Stanley Druckenmiller has maintained a strategic position in TEVA, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 7.57 M shares. Largest reduction occurred in Q4 2025, reducing 10.72 M shares.

Analysis based on 13F filings available since 2013 Q2

Stanley Druckenmiller's Teva Pharmaceutical Industries Limited (TEVA) Holding Value Over Time

Track share changes against reported price movement

Quarterly Teva Pharmaceutical Industries Limited (TEVA) Trades by Stanley Druckenmiller

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 -10.72 M Reduce 64.60% 5.87 M $31.21
Q3 2025 +625,000 Add 3.91% 16.59 M $20.20
Q2 2025 +1.09 M Add 7.32% 15.97 M $16.76
Q1 2025 +5.88 M Add 65.38% 14.88 M $15.37
Q4 2024 +7.57 M Add 530.09% 9 M $22.04
Q3 2024 +1.43 M New Buy 1.43 M $18.02
Q2 2015 -790,500 Sold Out 0 $0.00
Q1 2015 +790,500 New Buy 790,500 $62.30
Q3 2014 -1.24 M Sold Out 0 $0.00
Q4 2013 +1.24 M New Buy 1.24 M $40.08

Stanley Druckenmiller's Teva Pharmaceutical Industries Limited Investment FAQs

Stanley Druckenmiller first purchased Teva Pharmaceutical Industries Limited (TEVA) in Q4 2013, acquiring 1,241,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Stanley Druckenmiller has held Teva Pharmaceutical Industries Limited (TEVA) for 12 quarters since Q4 2013.

Stanley Druckenmiller's largest addition to Teva Pharmaceutical Industries Limited (TEVA) was in Q4 2024, adding 8,997,400 shares worth $198.3 M.

According to the latest 13F filing for Q4 2025, Stanley Druckenmiller's firm, Duquesne Family Office LLC, owns 5,874,870 shares of Teva Pharmaceutical Industries Limited (TEVA), valued at approximately $183.36 M.

As of the Q4 2025 filing, Teva Pharmaceutical Industries Limited (TEVA) represents approximately 4.08% of Stanley Druckenmiller's publicly disclosed stock portfolio, making it one of their key holdings.

Stanley Druckenmiller's peak holding in Teva Pharmaceutical Industries Limited (TEVA) was 16,593,935 shares, as reported at the end of Q3 2025.